Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Waterloo

$50,000.00

Refining baculovirus technology to enable controlled protein display on baculovirus vectors and enveloped virus-like particles

FY 2023-24

Summary
Motivation. The last 3 years - where we've experienced our first generational pandemic - follow two decades, which saw four types of viruses that caused major outbreaks: SARS coronavirus; avian and swine influenza viruses; Ebola virus; and Zika virus. Rapid and flexible technological response platforms are still needed. The COVID-19 pandemic is not the last virus pandemic we will live through. Opportunity. The baculovirus expression vector (BEV)-insect cell platform is approved in the production of human vaccines and widely used for animal vaccine production. This platform utilizes an insect virus (baculovirus), which has been genetically altered to carry a gene of interest, to infect insect cells, which then make the desired proteins for the vaccine. Because the hurdles of bringing products from this technology to market have been overcome, there is now a greater opportunity to better the technology and widen its scope of application. Hypothesis. The BEV--insect cell production platform can be refined to produce better vaccine particles by: removing native genes from baculovirus vectors; creating a library of DNA parts that can control gene transcription and protein expression; and by characterizing harvest material prior to downstream processing. Training. In this proposal, we are seeking support for 3 PhD students for the first three years and 2 additional graduate students (GS4 and GS5) starting in year 4. PhD1/GS4 will examine the effect of gene knock-out on foreign protein and baculovirus production. Certain regions in the baculovirus genome are not essential for their in vitro replication or protein production in cell culture. Using a CRISPR--Cas9 insect cell line developed in our lab, genes will be knocked down to screen for genes essential for gene expression and baculovirus replication. Subsequent removal of nonessential genes will yield a reduced genome recombinant baculovirus for efficient production of foreign protein and/or progeny viruses. PhD2 will develop a library of parts for protein display. The amount and location of antigenic protein displayed on a baculovirus should dictate its potential effectiveness as a vaccine; therefore, PhD2 will characterize how different parts of a protein (peptide domains) and different nucleic acid sequences (promoter regions) can be used to control the amount and location of antigenic proteins displayed on the baculovirus. PhD3/GS5 will concentrate on the separation and control over baculovirus contamination in virus--like particle (VLP) preparations. Removal of co--produced recombinant baculovirus vectors from enveloped VLPs in a scalable way has yet to be achieved. This work aims to investigate the separation of recombinant baculovirus from influenza, HIV and SARS-CoV-2 VLPs by showing the influence of the harvest material on the selection of downstream separation techniques.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2023-03666
Name nom
Aucoin, Marc
Department département
Chemical Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
50000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Not available
Research subject en
Non disponible
Research subject fr
Non disponible
Application title
Refining baculovirus technology to enable controlled protein display on baculovirus vectors and enveloped virus-like particles
Keyword
Animal cell culture; Baculovirus vectors; BEVS; Exosomes; Influenza VLP; Insect cells; Promoters; Protein expression; SARS VLP; Virus-like particles
Application summary
Motivation. The last 3 years - where we've experienced our first generational pandemic - follow two decades, which saw four types of viruses that caused major outbreaks: SARS coronavirus; avian and swine influenza viruses; Ebola virus; and Zika virus. Rapid and flexible technological response platforms are still needed. The COVID-19 pandemic is not the last virus pandemic we will live through. Opportunity. The baculovirus expression vector (BEV)-insect cell platform is approved in the production of human vaccines and widely used for animal vaccine production. This platform utilizes an insect virus (baculovirus), which has been genetically altered to carry a gene of interest, to infect insect cells, which then make the desired proteins for the vaccine. Because the hurdles of bringing products from this technology to market have been overcome, there is now a greater opportunity to better the technology and widen its scope of application. Hypothesis. The BEV--insect cell production platform can be refined to produce better vaccine particles by: removing native genes from baculovirus vectors; creating a library of DNA parts that can control gene transcription and protein expression; and by characterizing harvest material prior to downstream processing. Training. In this proposal, we are seeking support for 3 PhD students for the first three years and 2 additional graduate students (GS4 and GS5) starting in year 4. PhD1/GS4 will examine the effect of gene knock-out on foreign protein and baculovirus production. Certain regions in the baculovirus genome are not essential for their in vitro replication or protein production in cell culture. Using a CRISPR--Cas9 insect cell line developed in our lab, genes will be knocked down to screen for genes essential for gene expression and baculovirus replication. Subsequent removal of nonessential genes will yield a reduced genome recombinant baculovirus for efficient production of foreign protein and/or progeny viruses. PhD2 will develop a library of parts for protein display. The amount and location of antigenic protein displayed on a baculovirus should dictate its potential effectiveness as a vaccine; therefore, PhD2 will characterize how different parts of a protein (peptide domains) and different nucleic acid sequences (promoter regions) can be used to control the amount and location of antigenic proteins displayed on the baculovirus. PhD3/GS5 will concentrate on the separation and control over baculovirus contamination in virus--like particle (VLP) preparations. Removal of co--produced recombinant baculovirus vectors from enveloped VLPs in a scalable way has yet to be achieved. This work aims to investigate the separation of recombinant baculovirus from influenza, HIV and SARS-CoV-2 VLPs by showing the influence of the harvest material on the selection of downstream separation techniques.
University of Waterloo - $50,000 Grant (2023-24) | Canada Spends